mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

BACKGROUND: Cetuximab, a monoclonal blocking antibody against the epidermal growth factor receptor EGFR, has been approved for the treatment of squamous cell carcinomas of the head and neck (HNSCC). However, only few patients display long-term responses, prompting the search for cetuximab resistance...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Wang, Zhiyong, Martin, Daniel, Molinolo, Alfredo A., Patel, Vyomesh, Iglesias-Bartolome, Ramiro, Sol Degese, Maria, Vitale-Cross, Lynn, Chen, Qianming, Gutkind, J. Silvio
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133928/
https://ncbi.nlm.nih.gov/pubmed/25099740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju215
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker